Celgene Signs US$500 M Next-Generation Antibody Deal with Sutro Biopharma
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 1 (Table of Contents)
Published: 17 Jan-2013
DOI: 10.3833/pdr.v2013.i1.1871 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Sutro Biopharma has partnered with Celgene to design and develop antibody-drug conjugates (ADCs) and bispecific antibodies against two undisclosed Celgene targets...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018